# L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial (L Arginine in IUGR)

> **NCT00549575** · PHASE3 · TERMINATED · sponsor: **Nantes University Hospital** · enrollment: 44 (actual)

## Conditions studied

- Intra Uterine Growth Retardation

## Interventions

- **DRUG:** L ARG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00549575
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-07
- **Primary completion:** —
- **Final completion:** 2006-06
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** terminated
- **Last updated:** 2007-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00549575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00549575, "L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial (L Arginine in IUGR)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00549575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*